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reatment of Pulmonary
rterial Hypertension With the Selective
ndothelin-A Receptor Antagonist Sitaxsentan
obyn J. Barst, MD,* David Langleben, MD,† David Badesch, MD,‡ Adaani Frost, MD,§
. Clinton Lawrence, MD, Shelley Shapiro, MD,¶ Robert Naeije, MD,#
azzareno Galie, MD,** on behalf of the STRIDE-2 Study Group
ew York, New York; Montreal, Canada; Denver, Colorado; Houston, Texas; Atlanta, Georgia;
os Angeles, California; Brussels, Belgium; and Bologna, Italy
OBJECTIVES We sought to determine the optimal dose of the selective endothelin A (ETA) receptor
antagonist sitaxsentan for the treatment of pulmonary arterial hypertension (PAH); for
observation only, an open-label (OL) bosentan arm was included.
BACKGROUND Endothelin is a mediator of PAH. In a preliminary PAH study, the selective ETA receptor
antagonist sitaxsentan improved six-min walk (6MW) distance, World Health Organization
(WHO) functional class (FC), and hemodynamics.
METHODS In this double-blind, placebo-controlled 18-week study, 247 PAH patients (idiopathic, or
associated with connective tissue disease or congenital heart disease) were randomized; 245
patients were treated: placebo (n  62), sitaxsentan 50 mg (n  62) or 100 mg (n  61), or
OL (6MW tests, Borg dyspnea scores, and WHO FC assessments third-party blind)
bosentan (n  60). The primary end point was change in 6MW distance from baseline to
week 18. Secondary end points included change in WHO FC, time to clinical worsening, and
change in Borg dyspnea score.
RESULTS At week 18, patients treated with sitaxsentan 100 mg had an increased 6MW distance
compared with the placebo group (31.4 m, p 0.03), and an improved WHO FC (p 0.04).
The placebo-subtracted treatment effect for sitaxsentan 50 mg was 24.2 m (p  0.07) and for
OL bosentan, 29.5 m (p  0.05). The incidence of elevated hepatic transaminases (3 the
upper limit of normal) was 6% for placebo, 5% for sitaxsentan 50 mg, 3% for sitaxsentan 100
mg, and 11% for bosentan.
CONCLUSIONS Treatment with the selective ETA receptor antagonist sitaxsentan, orally once daily at a dose
of 100 mg, improves exercise capacity and WHO FC in PAH patients, with a low incidence
of hepatic toxicity. (J Am Coll Cardiol 2006;47:2049–56) © 2006 by the American College
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.01.057of Cardiology Foundation
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zulmonary arterial hypertension (PAH) is a progressive
isease characterized by vasoconstriction and structural
hanges in small pulmonary arteries, with increased pulmo-
ary artery pressure and pulmonary vascular resistance
ltimately leading to right heart failure and death (1).
ndothelin-1 (ET), a 21-amino acid peptide with vasocon-
trictor, mitogenic, and profibrotic effects (2), appears to
lay a key role in the pathobiology of PAH (3,4). Two
istinct ET receptor isoforms have been identified, ETA
nd ETB (5). EndothelinA receptors are expressed on
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3, 2005, accepted January 9, 2006.mooth muscle cells and cardiac myocytes; ETB receptors
re localized on vascular endothelial cells and smooth
uscle cells (6). Activation of ETA and ETB receptors on
mooth muscle cells results in vasoconstriction, and cell
roliferation and hypertrophy. Activation of ETB receptors
n endothelial cells leads to release of vasodilators, i.e., nitric
xide and prostacyclin, which also appear to have antipro-
iferative properties (7,8); in addition, endothelial ETB
eceptors are involved in the clearance of ET-1, primarily in
he vascular beds of the lungs, kidneys, and liver (9).
To date, bosentan, an ETA/ETB receptor antagonist, is
he only approved ET receptor antagonist for the treatment
f PAH (10,11). Sitaxsentan sodium is a selective ETA
eceptor antagonist, i.e., ETA:ETB ratio 6,500:1, with a
igh oral bioavailability (90%) and a long duration of
ction (half-life10 h in PAH patients) (12). Although the
itaxsentan To Relieve ImpaireD Exercise-1 (STRIDE-1)
tudy demonstrated improved exercise capacity (as assessed
y the six-min walk [6MW] test), World Health Organi-
ation (WHO) functional class (FC), cardiac index, and
ulmonary vascular resistance at both sitaxsentan doses
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Sitaxsentan for Pulmonary Arterial Hypertension May 16, 2006:2049–56tudied, i.e., 100 and 300 mg orally once daily, the safety
rofile was unacceptable with the 300-mg dose (13). The
bjective of this study was to confirm the efficacy of
itaxsentan and to determine the optimal dose on the basis
f overall risk-to-benefit considerations, i.e., safety and
olerability with therapeutic efficacy. On the basis of the
erception that 100 mg was the optimal dose in the
TRIDE-1 study, the STRIDE-2 study was powered to
how statistical difference of the primary efficacy end point
etween the sitaxsentan 100 mg and placebo groups. For
bservation only, an open-label (OL) (6MW tests, Borg
yspnea scores, and WHO FC assessments third-party
lind) bosentan arm was included.
ETHODS
tudy population. Patients in WHO FC II, III, or IV, 12
o 78 years of age, with symptomatic PAH despite treat-
ent with anticoagulants, vasodilators, diuretics, cardiac
lycosides, and/or supplemental oxygen (as clinically indi-
ated) were eligible for study participation if they met the
ollowing criteria: 1) PAH that was idiopathic, associated
ith connective tissue disease, or associated with repaired
trial septal defect, ventricular septal defect, or patent ductus
rteriosus at least one year before study enrollment; in
ddition, patients with PAH associated with an unrepaired
ecundum atrial septal defect (with a resting systemic
rterial oxygen saturation of 88% in room air) were
ligible; 2) mean pulmonary artery pressure 25 mm Hg at
est, pulmonary capillary wedge pressure or left ventricular
nd diastolic pressure15 mm Hg, and pulmonary vascular
esistance 3 Wood units (obtained by right heart cathe-
erization within six months of study enrollment [to confirm
he diagnosis of PAH]); and 3) baseline 6MW distance
150 m and 450 m. For patients 18 years of age, body
eight was 50 kg. Patients were excluded if they had
ignificant parenchymal lung disease, portal hypertension,
hronic liver disease, human immunodeficiency virus infec-
ion, hepatic dysfunction (hepatic transaminase level1.5
Abbreviations and Acronyms
ALT  alanine aminotransferase
ANCOVA  analysis of covariance
AST  aspartate aminotransferase
DSMB  Data Safety Monitoring Board
ET  endothelin
FC  functional class
INR  international normalized ratio
ITT  intent-to-treat
OL  open label
PAH  pulmonary arterial hypertension
6MW  six-min walk
STRIDE  Sitaxsentan To Relieve ImpaireD Exercise
study
ULN  upper limit of normal
WHO  World Health Organizationhe upper limit of normal [ULN]), renal insufficiency, cistory of left-sided heart disease, history of obstructive
leep apnea (treated or untreated), previously failed bosen-
an due to safety or inadequate clinical response (in the
udgment of the investigator), were on a prostaglandin,
hosphodiesterase inhibitor, or an ET receptor antagonist,
r had received any new type of PAH treatment within 30
ays before study entry.
The study was conducted according to ethical principles
tated in the Declaration of Helsinki (1996) and applicable
uidelines on good clinical practice. The protocol was
pproved by local institutional review committees; written
nformed consent was obtained from all patients.
tudy design and randomization. The study was an in-
ernational, multicenter, randomized, double-blind,
lacebo-controlled trial that treated 245 patients between
uly 2003 and January 2005, at 55 sites. Patients were
andomized to receive placebo, sitaxsentan 50 mg, or
itaxsentan 100 mg orally once daily, or OL bosentan for 18
eeks. The OL bosentan arm was included for observation
nly. The bosentan arm was OL at the standard dose, i.e.,
2.5 mg orally twice daily for four weeks, then increasing to
he maintenance dose of 125 mg orally twice daily. Because
osentan is only available commercially on a named-patient
asis, blinded drug supplies were not available. Patients
andomized to bosentan received OL drug (site personnel
btained medication through commercial channels utilizing
he bosentan Access Program); however, the efficacy rater
as blinded for the 6MW tests, WHO FC assessments, and
org dyspnea scores, i.e., third-party blind. Randomization
as performed centrally according to a computer-generated
andom number table. Randomization was 1:1:1:1. At the
nd of the 18-week study, all patients who completed the
8-week trial were eligible to enter an extension study.
atients who had been randomized, double-blind, to sitax-
entan 50 mg or 100 mg in the STRIDE-2 study received
itaxsentan 100 mg in the extension; patients who had been
andomized to OL bosentan in the STRIDE-2 study
ontinued OL bosentan in the extension. Patients who had
een randomized, double-blind, to placebo in the
TRIDE-2 study were randomized to either sitaxsentan
00 mg or OL bosentan in the extension. The STRIDE-2
andomization for patients randomized to sitaxsentan 50 mg
r 100 mg in the STRIDE-2 study remained double-blind
ntil the STRIDE-2 study database was locked; the
TRIDE-2 randomization for patients randomized to pla-
ebo in the STRIDE-2 study and randomized to sitaxsen-
an 100 mg in the extension study remained double-blind
ntil the STRIDE-2 study database was locked. Patients
eceiving OL bosentan remained third-party blind through-
ut the STRIDE-2 study and in the extension until the
TRIDE-2 study database was locked.
utcome measures. Patients were evaluated at baseline
nd at weeks 6, 12, and 18. The primary end point was
hange from baseline in 6MW distance at week 18. Sec-
ndary end points included change in WHO FC, time to
linical worsening, and change in Borg dyspnea score.
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May 16, 2006:2049–56 Sitaxsentan for Pulmonary Arterial Hypertensionafety was assessed by adverse events and laboratory evalu-
tions. Patients receiving sitaxsentan or placebo were dis-
ontinued if they had an elevation in alanine aminotrans-
erase (ALT) or aspartate aminotransferase (AST) 5
LN, or if they had an elevation in total bilirubin 2
LN with an ALT or AST 3 ULN. For OL bosentan
atients, liver function abnormalities were handled accord-
ng to the bosentan package insert, i.e., a patient was to be
iscontinued if ALT or AST exceeded 8 ULN, although
he patient could undergo bosentan dosage reductions or
emporary cessation for lesser elevations in ALT or AST at
he discretion of the investigator. Investigators had the
ption to discontinue patients from the study if patients had
combined deterioration in WHO FC and 15% decrease
n 6MW distance from baseline. Patients completing the
8-week study (all groups) or prematurely discontinuing
50-mg or placebo groups) were eligible to enter the
TRIDE-2X extension study.
tatistical analysis. Data are reported as mean  SD
nless otherwise stated. The STRIDE-2 study was powered
o identify statistical differences in efficacy between the
00-mg sitaxsentan and placebo groups. Comparisons be-
ween sitaxsentan and OL bosentan were observational only
ecause of the inability to double-blind the bosentan arm.
s defined in the protocol, for reporting statistical signifi-
ance of efficacy, adjustments were made for multiple
omparisons of multiple end points in treatment groups.
tatistical significance was reported only if the conditions
or the multiple comparison strategy were met; a p value
0.05 was considered statistically significant.
The primary end point was the change in 6MW distance
rom baseline to week 18. On the basis of the STRIDE-1
tudy data, an approximate 35-m difference between the 100
g sitaxsentan and the placebo treatment groups, with a
tandard deviation of 58 m in each treatment group in the
hange from baseline in 6MW distance at week 18, was
sed to calculate the sample size of approximately 60
ubjects per treatment group to detect statistically significant
ifferences with 90% power at the significance level of 0.05
sing a two-sided Student t test. The null hypothesis of no
ifference between treatment groups was tested using the
on-parametric analysis of covariance (ANCOVA), ad-
usted for baseline values. All missing values were imputed
sing the last observation carried forward method. If the
atient was unable to perform the 6MW test because of
linical worsening or death, the 6MW distance was assigned
value of 0 m with a Borg dyspnea score of 10 for the visit.
Secondary end points were change from baseline to week
8 in WHO FC, time to clinical worsening, and Borg
yspnea score. Change from baseline in WHO FC was
ummarized with frequency counts and percentages, and
reatment difference was analyzed using the Cochran-
antel-Haenszel test, controlling for baseline WHO FC.
he Kaplan-Meier method was used to estimate time to
linical worsening. Time to clinical worsening was defined
s the number of days between the first dose date and the srst date when clinical worsening occurred. Patients who
iscontinued or completed the study without having a
linical worsening event were censored at their last visit.
linical worsening was defined as any of the following:
ospitalization for PAH, death, transplantation, atrial sep-
ostomy, initiation of new chronic PAH treatment, or
ombined WHO FC deterioration and 15% decrease in
MW distance from baseline. Treatment differences were
valuated using log-rank tests. The change in Borg dyspnea
core from baseline to week 18 was analyzed using the
on-parametric ANCOVA, adjusted for baseline values.
All efficacy analyses were conducted on the intent-to-
reat (ITT) population, which was defined as all randomized
atients who took any dose of study drug and performed at
east one valid post-baseline 6MW test.
nterim monitoring. An independent external Data Safety
onitoring Board (DSMB) conducted an interim safety
valuation on the basis of adverse events and laboratory data
fter 60 patients completed week 12 assessments. In addi-
ion, the DSMB reviewed serious adverse events and ele-
ated hepatic transaminases by blinded, masked treatment
n an ongoing basis. Only the DSMB was authorized to
equest unblinding of safety data by treatment groups.
ESULTS
atients. Two hundred forty-seven patients were random-
zed, 245 patients treated: 62 patients received placebo, 62
atients received sitaxsentan 50 mg, 61 patients received
itaxsentan 100 mg, and 60 patients received OL bosentan.
ive patients did not have a valid post-baseline 6MW test;
.e., there were 240 patients in the ITT population for
fficacy end points. Thirty-one patients prematurely discon-
inued the study (Fig. 1). The primary reason given for
iscontinuation in the placebo group (n 11) was elevation
f AST or ALT 3 ULN and total bilirubin 2 ULN
n one patient, WHO FC deterioration and 15% decrease
n 6MW distance in two patients, initiation of new chronic
AH treatment in five patients, adverse event in two
atients, and sponsor decision in one patient. In the
itaxsentan 50 mg group, eight patients discontinued:
HO FC deterioration and 15% decrease in 6MW
istance in one patient, initiation of new chronic PAH
reatment in three patients, adverse event in one patient,
atient decision in two patients, and investigator decision in
ne patient. In the sitaxsentan 100 mg group, four patients
iscontinued: elevation of AST or ALT 5 ULN in one
atient, initiation of new chronic PAH treatment in two
atients, and patient decision in one patient. In the OL
osentan group, eight patients discontinued: elevation in
LT or AST 8 ULN in two patients, WHO FC
eterioration and 15% decrease in 6MW distance in one
atient, and initiation of new chronic PAH treatment in five
atients. The patients who prematurely discontinued the
tudy were not significantly different than the overall study
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Sitaxsentan for Pulmonary Arterial Hypertension May 16, 2006:2049–56opulation, judging from demographic and clinical charac-
eristics at study enrollment.
Patient characteristics for study entry are shown in
able 1. Overall, PAH was idiopathic PAH in 59% of
atients, associated with connective tissue disease in 30% of
atients, and associated with congenital heart disease (as
efined in the inclusion criteria) in 11% of patients. Baseline
haracteristics were similar for the four treatment groups,
ith the exception of baseline 6MW distance, age, and
eight. The distance of 6MW at baseline, therefore, was
sed as a covariate for efficacy analyses.
xercise capacity. At week 18 (Fig. 2), the change from
aseline in 6MW distance was 17.8 m in the sitaxsentan 50
g group, 24.9 m in the sitaxsentan 100 mg group, and
3.0 m in the OL bosentan group. In contrast, a decrease of
.5 m from baseline occurred in the placebo group at week
8, i.e., the placebo-subtracted treatment effects at week 18
n the sitaxsentan groups were 24.2 m (p  0.07) for the
0-mg group and 31.4 m (p  0.03; 95% confidence
nterval 5.37, 57.44) for the 100-mg group. For the OL
hird-party blind bosentan-treated patients, the placebo-
ubtracted treatment effect at week 18 was 29.5 m (p 
.05).
HO FC. At week 18 (Fig. 3), the change from baseline
n WHO FC was significantly better for the sitaxsentan
00-mg group compared with those receiving placebo (p 
.04), i.e., 98% of the sitaxsentan 100-mg patients improved
HO FC (13%) or remained unchanged (85%), whereas
7% of the placebo patients improved WHO FC (10%) or
emained unchanged (77%). No significant improvements
ere seen after 18 weeks in WHO FC versus placebo in
ither the sitaxsentan 50-mg group or the OL bosentan
roup. Worsening in WHO FC at week 18 (vs. baseline)
ccurred in 13% of placebo patients, 13% of sitaxsentan
0-mg patients, 2% of sitaxsentan 100-mg patients, and 9%
Figure 1. Patient disposition. BID  twif OL bosentan patients. sime to clinical worsening. Twenty-nine patients (10
lacebo, 6 sitaxsentan 50 mg, 4 sitaxsentan 100 mg, and 9
L bosentan patients) experienced at least one clinical
orsening event; the most frequently reported reasons for
linical worsening were initiation of new chronic PAH
reatment (18 patients); combined deterioration in WHO
C and15% decrease in 6MW distance (11 patients); and
ospitalization for worsening PAH (10 patients) (Table 2).
uring the 18-week study, sitaxsentan 100 mg trended
oward an increase in the time to clinical worsening versus
lacebo (p  0.08); there were no differences for either the
itaxsentan 50-mg group (p  0.27) or the OL bosentan
roup (p  0.80) compared with patients receiving placebo.
org dyspnea score. Change from baseline to week 18 in
org dyspnea score in the sitaxsentan 100-mg group
howed a nonsignificant improvement (reduction in score),
hile the placebo group worsened (0.01 vs. 0.19; p 
.6603). Changes from baseline to week 18 in Borg dyspnea
core in the sitaxsentan 50-mg and OL bosentan groups also
ere not significantly different from patients receiving
lacebo.
afety. The number of patients reporting adverse events in
ach treatment group was similar; i.e., 90% of placebo
atients, 86% of sitaxsentan 50-mg patients, 93% of sitax-
entan 100-mg patients, and 89% of OL bosentan patients
xperienced at least one adverse event. Treatment-related
dverse events were reported in 29% of placebo patients,
6% of sitaxsentan 50-mg patients, 46% of sitaxsentan
00-mg patients, and 56% of OL bosentan patients. Serious
dverse events occurred most often in placebo patients.
reatment-related side effects are listed in Table 3; edema,
asal congestion, fatigue, and insomnia were more fre-
uently reported by sitaxsentan patients than by placebo
atients, with a frequency that appeared to be dose-related
Table 3). Eighteen patients discontinued the STRIDE-2
ay; OL  open label; QD  once daily.tudy because of an adverse event: six (10%) placebo
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May 16, 2006:2049–56 Sitaxsentan for Pulmonary Arterial Hypertensionatients, four (7%) sitaxsentan 50-mg patients, two (3%)
itaxsentan 100-mg patients, and six (10%) OL bosentan
atients.
Serious adverse events were more than twice as frequent
n the placebo group (31%) compared with any of the other
hree groups, and were most often related to PAH worsen-
ng. Two patients in the placebo group died (due to
igure 2. Mean (SE) change in six-min walk (6MW) distance from basel
able 1. Demographic and Clinical Characteristics at Study Entr
pen-Label Bosentan Groups
Characteristic
Placebo QD
(n  62)
ender
Female 47 (76)
ge (yrs)
Mean 53  15
Range 22–77
thnicity
White 46 (74)
ause of PAH
Idiopathic 37 (60)
Connective tissue disease 17 (27)
Congenital heart disease 7 (11)
revious or concomitant treatment*
Anticoagulants 32 (52)
Diuretics 42 (68)
Calcium-channel blockers 25 (40)
Digoxin 12 (19)
Supplemental oxygen 25 (40)
HO functional class
II 23 (37)
III 35 (57)
IV 4 (6)
-min walk distance, m 321  85
ean pulmonary artery pressure, mm Hg† 49  14
ardiac index, l/min/m2† 2.4  0.7
ulmonary vascular resistance, Wood units† 11  8
ll values shown are based on safety population. *Previous and concomitant treatm
atheterization within six months of study entry to confirm the diagnosis of PAH. A
r mean  SD.
BID  twice a day; PAH  pulmonary arterial hypertension; QD  once daily;abel (OL) bosentan groups. *p  0.03 (95% confidence interval 5.37, 57.44) fo
.05 for OL bosentan vs. placebo, and p  0.07 for 50-mg sitaxsentan vs. placultiple-organ failure), 5 and 15 days after premature
iscontinuation from the study. Serious adverse events of
levated hepatic transaminases considered related to a study
rug occurred in one sitaxsentan 100-mg patient and in one
L bosentan patient. Bleeding adverse events, most com-
only epistaxis, were reported in three placebo patients,
ight sitaxsentan 50-mg patients, six sitaxsentan 100-mg
week 18 in the placebo, sitaxsentan 50-mg, sitaxsentan 100-mg, and open
the Placebo, Sitaxsentan 50 mg, Sitaxsentan 100 mg, and
xsentan
mg QD
 62)
Sitaxsentan
100 mg QD
(n  61)
Bosentan
125 mg BID
(n  60)
Overall
(n  245)
3 (86) 43 (71) 47 (78) 190 (78)
 13 55  14 49  16 54  15
4–77 16–78 18–77 14–78
8 (77) 52 (85) 48 (80) 194 (79)
4 (55) 39 (64) 34 (57) 144 (59)
9 (31) 18 (29) 20 (33) 74 (30)
9 (14) 4 (7) 6 (10) 26 (11)
0 (48) 25 (41) 29 (48) 116 (47)
4 (55) 38 (62) 36 (60) 150 (61)
3 (53) 22 (36) 19 (32) 99 (40)
7 (11) 9 (15) 9 (15) 37 (15)
9 (31) 18 (30) 20 (33) 82 (33)
1 (34) 26 (42) 22 (37) 92 (37)
8 (61) 34 (56) 37 (62) 144 (59)
3 (5) 1 (2) 1 (2) 9 (4)
 80 360  72 337  78 337  80
 15 45  12 50  15 48  14
 1.0 2.4  0.6 2.4  0.6 2.4  0.8
 7 10  7 11  5 11  7
defined as treatment taken at any time 3 days before. †Obtained by right heart
er characteristics are at baseline. Day 0 through study termination. Values are n (%)
 World Health Organization.ine toy in
Sita
50
(n
5
57
1
4
3
1
3
3
3
1
2
3
328
48
2.7
10
ent is
ll othr comparison between the 100-mg dose of sitaxsentan and placebo, **p 
ebo.
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Sitaxsentan for Pulmonary Arterial Hypertension May 16, 2006:2049–56atients, and four OL bosentan patients. None of the
leeding events were considered serious or required hospi-
alization, transfusion, or treatment.
Liver abnormalities have been recognized as a class effect
ssociated with endothelin receptor antagonists (10,11,13,14).
he incidence of liver enzyme abnormalities (hepatic
ransaminase values 3 ULN) was 6% for the placebo
roup, 5% for those receiving sitaxsentan 50 mg, 3% for the
itaxsentan 100-mg patients, and 11% for the OL bosentan
roup. Elevations in liver enzymes were associated with
rug discontinuation in one placebo patient, one 50-mg
atient (3 ULN, with the reason for discontinuation
eported as investigator decision), one 100-mg patient, and
wo OL bosentan patients. Liver enzyme abnormalities
eversed in all sitaxsentan and bosentan cases.
Because of the effect of sitaxsentan on inhibition of the
YP2C9 P450 enzyme, the principal hepatic enzyme in-
olved in warfarin metabolism, an 80% reduction in the
arfarin dose for patients not randomized to OL bosentan
as used at baseline, with adjustment as needed to maintain
igure 3. Change in World Health Organization functional class from base
abel (OL) bosentan groups. *p 0.04 for comparison between the 100-mg
0-mg group or the OL bosentan group vs. placebo. BL  baseline.
able 2. Incidence of Clinical Worsening*
Event
Placebo‡ QD
(n  62)
umber of patients 10
eath —
ransplantation —
ospitalization for PAH 4
nitiation of new chronic PAH treatment 4§
WHO FC and 215% in 6MW 2
This table presents the number of patients; if a patient had more than one event, th
our treatment groups using the Fisher exact test. ‡Two patients in the placebo group
nd were not counted as events in the clinical worsening analysis. §Sitaxsentan n 1; b
 1; oxygen n  2. #SC treprostinil n  1; sitaxsentan n  1.
FC  functional class; OL  open-label; 6MW  six-min walk; other abbreviations atherapeutic international normalized ratio (INR). The
roportion of patients with an INR 3.5 was comparable
or the sitaxsentan and placebo groups (33% to 42%) and
ower for the OL bosentan group (20%) (p  0.1744).
osage adjustments occurred with similar frequencies for
he four groups (63 to 70 adjustments per group). Daily
arfarin dosages at week 18 were: 3.7  2.7 mg/day for
lacebo patients, 2.8 1.2 mg/day for 50-mg sitaxsentan
atients, 2.1  1.0 mg/day for 100-mg sitaxsentan patients,
nd 5.1  2.9 mg/day for OL bosentan patients. Warfarin
oses were similar to baseline for placebo patients, lower
han baseline in the sitaxsentan patients, and higher than
aseline in the bosentan patients.
Decreases in hemoglobin in sitaxsentan- and OL
osentan-treated patients were observed as early as week
wo and remained stable throughout the 18-week study
mean change from baseline to week 18: placebo,0.2 g/dl;
0 mg sitaxsentan, 0.2 g/dl; 100 mg sitaxsentan, 0.5
/dl; and OL bosentan, 0.5 g/dl). A small and similar
umber of patients, i.e., one to three patients, for each
week 18 in the placebo, sitaxsentan 50-mg, sitaxsentan 100-mg, and open
f sitaxsentan and placebo; there was no difference for either the sitaxsentan
xsentan
g QD
 62)
Sitaxsentan
100 mg QD
(n  61)
OL Bosentan
125 mg BID
(n  60) p Value†
6 4 9 0.1733
— — — —
— — — —
1 1 3 0.4577
4 3¶ 2# 1.000
1 — 4 0.1977
event appears in the table. †The p value was obtained for the comparison among all
of multi-organ failure) 5 and 15 days after premature discontinuation from the study,
n n 2; oxygen n 1. Sitaxsentan n 2; sildenafil n 1; digoxin n 1. ¶Digoxinline toSita
50 m
(n
e first
died (
osentas in Table 1.
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o below the normal range by week 18.
The DSMB did not request that data be unblinded
uring the study.
ISCUSSION
n a preliminary, randomized, controlled PAH trial
STRIDE-1), although both 100- and 300-mg doses of
itaxsentan improved exercise capacity (as assessed by the
MW test), WHO FC, cardiac index, and pulmonary
ascular resistance compared with placebo, the incidence of
levated hepatic transaminases (3ULN), serious adverse
vents, and discontinuation were higher with the 300-mg
ose, consistent with a dose response for safety and tolera-
ility. On this basis, 100 mg was chosen as the highest dose
o be studied in future trials.
On the basis of overall safety, tolerability, and efficacy, the
TRIDE-2 study demonstrated that 100 mg is the optimal
ose of sitaxsentan for treating symptomatic PAH. Treat-
ent with sitaxsentan 100 mg significantly improved exer-
ise capacity and WHO FC compared with placebo; 50 mg
as subtherapeutic, and based on the results from the
TRIDE-1 study, 300 mg was unacceptable for safety.
mong the treatment-related side effects, edema, nasal
ongestion, fatigue, and insomnia were more frequently
eported by the sitaxsentan-treated patients than by the
lacebo patients.
Patients with PAH are frequently anticoagulated; sitax-
entan inhibits warfarin metabolism via inhibition of
YP2C9, and bosentan induces CYP2C9 (15). Dosage
djustments in warfarin were equally frequent in all four
roups, with mean daily warfarin doses lower for
itaxsentan-treated patients (in a dose-dependent manner)
ompared with patients receiving placebo, and higher for
L bosentan-treated patients compared with the placebo
roup. Although increases in INR 3.5 occurred in a
ignificant number of patients receiving placebo or sitaxsen-
an, bosentan patients were relatively protected from this
ffect, consistent with enzyme induction of warfarin
etabolism with bosentan. However, in all groups, con-
Table 3. Treatment-Related Side Effects*
Adverse Events
(No. of Patients)
Placebo QD
(n  62)
Sitaxse
50 mg
(n 
Edema 5 5
Nasal/sinus congestion 4 2
Headache 5 5
Nausea 0 3
Fatigue 2 1
Dizziness 2 2
Insomnia 0 1
*This table presents the number of patients for each adverse
was obtained for the comparison among all four treatment g
Abbreviations as in Table 1.omitant therapy with warfarin was well tolerated, andleeding events were rare, non-serious, and did not require
reatment.
Liver function abnormalities have been previously re-
orted with endothelin receptor antagonists and can lead to
reatment discontinuation. In the STRIDE-1 study and its
xtension (median exposure 26 weeks), 5% of patients
reated with sitaxsentan 100 mg had 3 ULN hepatic
ransaminases; all transaminase increases were reversible.
lthough the STRIDE-2 study was not powered to assess
omparison between sitaxsentan 100 mg and OL bosentan,
uring this 18-week study, the incidence of elevated hepatic
ransaminases was 3% for sitaxsentan 100 mg and 11% for
L bosentan (i.e., the same as the rate reported in the
osentan package insert).
Pulmonary arterial hypertension is a rare and serious
isease. Despite the scientific interest in comparing an ETA
elective receptor antagonist with an ETA/ETB receptor
ntagonist, it was not possible to conduct a trial of sufficient
ower (in a reasonable period of time) to directly compare
he efficacy of sitaxsentan with bosentan. Only a trial of
onsiderable size, with both treatments administered
ouble-blind, could resolve this question with certainty.
ecause of a unique distribution program, it was not
ossible to double-blind the bosentan arm in this study.
ONCLUSIONS
reatment with the selective ETA receptor antagonist
itaxsentan (at a dose of 100 mg orally once daily) improves
xercise capacity and WHO FC in symptomatic PAH
atients, with a low incidence of hepatic toxicity.
eprint requests and correspondence: Dr. Robyn J. Barst,
olumbia University College of Physicians and Surgeons, 3959
roadway, BHN 2-255, New York, New York 10032. E-mail:
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